# EDGAR Filing Document

**Accession Number:** 0001824569
**File Stem:** 0001193125-26-013015
**Filing Date:** 2026-1
**Character Count:** 21831
**Document Hash:** 82dfe0184b41b3a17f761b4c3abe732e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-013015.hdr.sgml**: 20260114

**ACCESSION NUMBER**: 0001193125-26-013015

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 3

**FILED AS OF DATE**: 20260114

**DATE AS OF CHANGE**: 20260114

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Aktis Oncology, Inc.
- **CENTRAL INDEX KEY:** 0002035832
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 852584233
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-95421
- **FILM NUMBER:** 26533813

**BUSINESS ADDRESS:**
- **STREET 1:** 17 DRYDOCK AVENUE
- **STREET 2:** SUITE #17-401
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210
- **BUSINESS PHONE:** 978-237-4380

**MAIL ADDRESS:**
- **STREET 1:** 17 DRYDOCK AVENUE
- **STREET 2:** SUITE #17-401
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** VV Manager II, LLC
- **CENTRAL INDEX KEY:** 0001824569

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

**BUSINESS ADDRESS:**
- **STREET 1:** 40 BROAD STREET
- **STREET 2:** SUITE 201
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02109
- **BUSINESS PHONE:** 6176489100

**MAIL ADDRESS:**
- **STREET 1:** 40 BROAD STREET
- **STREET 2:** SUITE 201
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02109

### Attached PDF Documents

**Attachment 1:** `ck0000000000-ex99_1.pdf`

_No text found in this document._

**Attachment 2:** `ck0000000000-ex99_7.pdf`

_No text found in this document._

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**Aktis Oncology, Inc.**

*(Name of Issuer)*

**Common Stock, $0.0001 par value per share**

*(Title of Class of Securities)*

**01021M104**

*(CUSIP Number)*

**Jean-Philippe Kouakou-Zebouah**<br>Vida Ventures<br>10100 Santa Monica Boulevard, Suite 1500<br>Los Angeles CA 90067<br>(818) 800-5840

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**01/12/2026**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **01021M104** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Vida Ventures II, LLC** | Name of reporting person<br>**Vida Ventures II, LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**5671825.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**5671825.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**5671825.00** | Aggregate amount beneficially owned by each reporting person<br>**5671825.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**10.6%** | Percent of class represented by amount in Row (11)<br>**10.6%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** (1) All shares are held of record by Vida II (as defined in Item 2(a) below). VV Manager II (as defined in Item 2(a) below) is the manager of Vida II and may be deemed to have voting, investment and dispositive power with respect to these securities. The Management Committee Members (as defined in Item 2(a)), along with the Investment Committee Members (as defined in Item 2(a)), may be deemed to share voting, investment and dispositive power over the shares held by Vida II.

(2) This percentage is calculated based upon 53,296,950 shares of Common Stock outstanding (which reflects the full exercise by the underwriters of their option to purchase additional shares of Common Stock in connection with the Offering (as defined in Item 3 below), as set forth in the Issuer's prospectus on Form 424(b)(4) and filed with the United States Securities and Exchange Commission (the "Commission") on January 9, 2026 (the "Prospectus").

| **CUSIP No.** | **01021M104** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Vida Ventures II-A, LLC** | Name of reporting person<br>**Vida Ventures II-A, LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**157387.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**157387.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**157387.00** | Aggregate amount beneficially owned by each reporting person<br>**157387.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0.3%** | Percent of class represented by amount in Row (11)<br>**0.3%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** (1) All shares are held of record by Vida II-A (as defined in Item 2(a) below). VV Manager II is the manager of Vida II-A and may be deemed to have voting, investment and dispositive power with respect to these securities. The Management Committee Members, along with the Investment Committee Members, may be deemed to share voting, investment and dispositive power over the shares held by Vida II-A.

(2) This percentage is calculated based upon 53,296,950 shares of Common Stock outstanding as set forth in the Prospectus.

| **CUSIP No.** | **01021M104** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**VV Manager II LLC** | Name of reporting person<br>**VV Manager II LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**5829212.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**5829212.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**5829212.00** | Aggregate amount beneficially owned by each reporting person<br>**5829212.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**10.9%** | Percent of class represented by amount in Row (11)<br>**10.9%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** (1) Consists of (i) 5,671,825 shares held of record by Vida II and (ii) 157,387 shares held of record by Vida II-A. VV Manager II is the manager of Vida II and Vida II-A and may be deemed to have voting, investment and dispositive power with respect to the shares held by each of Vida II and Vida II-A. The Management Committee Members, along with the Investment Committee Members, may be deemed to share voting, investment and dispositive power over the shares held by each of Vida II and Vida II-A.

(2) This percentage is calculated based upon 53,296,950 shares of Common Stock outstanding as set forth in the Prospectus.

| **CUSIP No.** | **01021M104** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Helen Kim** | Name of reporting person<br>**Helen Kim** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**2103.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**5829212.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**2103.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**5829212.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**5831315.00** | Aggregate amount beneficially owned by each reporting person<br>**5831315.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**10.9%** | Percent of class represented by amount in Row (11)<br>**10.9%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** (1) Consists of 2,103 shares subject to stock options granted to Ms. Kim in her capacity as a director of the Issuer that are exercisable as of the date of filing of this Schedule or within 60 days thereafter.

(2) Consists of (i) 5,671,825 shares held of record by Vida II and (ii) 157,387 shares held of record by Vida II-A. VV Manager II is the manager of Vida II and Vida II-A and may be deemed to have voting, investment and dispositive power with respect to the shares held by each of Vida II and Vida II-A. The Management Committee Members, along with the Investment Committee Members, may be deemed to share voting, investment and dispositive power over the shares held by each of Vida II and Vida II-A

(3) This percentage is calculated based upon 53,296,950 shares of Common Stock outstanding as set forth in the Prospectus.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, $0.0001 par value per share

**(b) Name of Issuer:**
Aktis Oncology, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
17 Drydock Avenue, Suite #17-401, Boston, MA, 02210

**Item 4. Purpose of Transaction**

The information set forth in Item 3 of this Statement is incorporated herein by reference. The Reporting Persons hold the securities of the Issuer for general investment purposes. The Reporting Persons may, from time to time, depending on prevailing market, economic and other conditions, acquire additional shares of Common Stock or other securities of the Issuer, dispose of any such securities, or engage in discussions with the Issuer concerning such acquisitions or dispositions or further investments in the Issuer. The Reporting Persons intend to review their investment in the Issuer on a continuing basis and, depending upon the price and availability of shares of Common Stock or other securities of the Issuer, subsequent developments affecting the Issuer, the Issuer's business and prospects, other investment and business opportunities available to the Reporting Persons, general stock market and economic conditions, tax considerations and other factors considered relevant, may decide at any time to increase or to decrease the size of their investment in the Issuer in the open market, in privately negotiated transactions, pursuant to 10b5-1 trading plans or otherwise.

The Reporting Individual is a member of the Issuer's board of directors. In addition, Ms. Kim, in her capacity as a director, may be entitled to receive cash compensation and equity compensation, including stock options or other equity awards, pursuant to the Issuer's non-employee director compensation policy, which became effective upon the effective date of the Registration Statement (as defined below).

Except as set forth in this Item 4 and Item 6 below, none of the Reporting Persons has a present plan or proposal that relates to or would result in any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D of the Act. However, each of the Reporting Persons reserves the right to propose or participate in future transactions which may result in one or more of such actions, including but not limited to, an extraordinary corporate transaction, such as a merger, reorganization or liquidation, sale of a material amount of assets of the Issuer or its subsidiaries, or other transactions which might have the effect of causing the Common Stock to become eligible for termination of registration under Section 12(g) of the Act. The Reporting Persons may engage from time to time in ordinary course transactions with financial institutions with respect to the securities described herein.

The Reporting Persons have previously retained the right and continue to retain the right, based on all relevant factors and subject to applicable law or other restrictions, at any time and from time to time, to change their investment intent at any time, to acquire additional shares of Common Stock or other securities of the Issuer, sell or otherwise dispose of all or part of the Common Stock beneficially owned by them (or any shares of Common Stock into which such securities are converted) from time to time, in each case in open market or private transactions, block sales or otherwise or pursuant to ordinary stock exchange transactions effected through one or more broker-dealers whether individually or utilizing specific pricing or other instructions (including by means of Rule 10b5-1 programs), and review or reconsider their position, change their purpose, take other actions or formulate and implement plans or proposals with respect to any of the foregoing.

**Item 5. Interest in Securities of the Issuer**

**(a)**
See Items 7-11 of the cover pages of this Schedule 13D and Item 2 above.

**(b)**
See Items 7-11 of the cover pages of this Schedule 13D and Item 2 above.

**(c)**
Except as reported in this Statement, none of the Reporting Persons has affected any transactions in the Issuer's securities within the past 60 days.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

In connection with its purchase of shares of the Issuer's Series B Redeemable Convertible Preferred Stock financing, Vida II, Vida II-A and certain of the Issuer's other investors entered into a Third Amended and Restated Investors' Rights Agreement, dated September 20, 2024, with the Issuer (the "Rights Agreement"). The Rights Agreement grants certain rights to Vida II, Vida II-A, including certain demand, piggyback and Form S-3 registration rights with respect to the registrable securities held by them. The terms and provisions of the Rights Agreement are described more fully in the Issuer's Registration Statement on Form S-1/A (File No. 333-292283) declared effective by the Commission on January 7, 2026 (the "Registration Statement"), and the above summary is qualified by reference to such description and the full text of the Rights Agreement, which is filed as Exhibit 2 to this Statement and is incorporated herein by reference.

In connection with the Offering, each of Vida II, Vida II-A and Ms. Kim has entered into lock-up agreements, pursuant to which each of Vida II, Vida II-A and Ms. Kim have agreed, subject to certain exceptions, not to sell, transfer or otherwise convey any of the Issuer's securities held by each of the Funds for 180 days following the date of the Offering. The terms and provisions of such lock-up agreements are described more fully in the Registration Statement, and the above summary is qualified by reference to such description and the full text of the lock-up agreement, a form of which is filed as Exhibit 3 to this Statement and is incorporated herein by reference.

Ms. Kim, in her capacity as a director, may be entitled to receive cash compensation and equity compensation, including stock option or other equity awards, pursuant to the Issuer's 2026 Equity Incentive Plan (the "2026 Plan"), and the Issuer's non-employee director compensation policy (the "Compensation Plan"). The terms and provisions of the 2026 Plan and the Compensation Plan are described in the Registration Statement, and the above summary is qualified by reference to such description and the full text of which is filed as Exhibit 4 and Exhibit 5 to this Statement and are incorporated herein by reference.

The Issuer has entered into an indemnification agreement with each of its directors and executive officers, including Ms. Kim. The indemnification agreement requires the Issuer, among other things, to Ms. Kim for some expenses, including attorneys' fees, judgments, fines and settlement amounts incurred by Ms. Kim in any action or proceeding arising out of her respective services as director. The terms and provisions of the indemnification agreement are described more fully in the Registration Statement, and the above summary is qualified by reference to such description and the full text of the Registration Statement, which is filed as Exhibit 6 to this Statement and is incorporated herein by reference.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Vida Ventures II, LLC

**Signature:** By: VV Manager II, LLC, its Manager, /s/ Jean-Philippe Kouakou-Zebouah

**Name/Title:** Authorized Signatory

**Date:** 01/14/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Vida Ventures II-A, LLC

**Signature:** By: VV Manager II, LLC, its Manager, /s/ Jean-Philippe Kouakou-Zebouah

**Name/Title:** Authorized Signatory

**Date:** 01/14/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** VV Manager II LLC

**Signature:** /s/ Jean-Philippe Kouakou-Zebouah

**Name/Title:** Authorized Signatory

**Date:** 01/14/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Helen Kim

**Signature:** /s/ Jean-Philippe Kouakou-Zebouah

**Name/Title:** Attorney-in-Fact for Helen Kim

**Date:** 01/14/2026